Tool
Stock screener
Filter the 300 large-cap US stocks StockVane tracks, then sort by any column. Results carry the same Quant Rating shown on each stock’s page.
Top Quant-ratedLarge-cap dividend payersCheap & top-ratedBeaten-down (down 20%+ 1yr)High yield (4%+)Mega-cap winners
8 matches
| Company | 60d | Last | Chg% | Mkt cap | P/E | Yield | 1-yr | Quant ↓ |
|---|---|---|---|---|---|---|---|---|
| Merck & CoMRK | 147.86 | -2.02% | $364.80B | 118.29 | 2.27% | +91.7% | B 89 | |
| Johnson & JohnsonJNJ | 268.52 | -0.25% | $647.09B | 31.15 | 1.95% | +57.0% | B 80 | |
| Eli Lilly and CoLLY | 1,156.42 | -1.17% | $1.09T | 38.82 | 0.56% | +58.1% | B 77 | |
| Bristol-Myers SquibbBMY | 61.31 | -1.52% | $125.23B | 13.50 | 4.09% | +47.0% | B 71 | |
| Gilead SciencesGILD | 150.30 | -1.55% | $186.37B | -- | 2.14% | +37.2% | C 66 | |
| GlaxoSmithKlineGSK | 49.80 | -1.82% | $99.76B | 15.84 | 3.56% | +30.1% | D 57 | |
| Novartis AGNVS | 142.72 | +1.02% | $271.27B | 21.56 | 3.32% | +19.9% | D 47 | |
| AstraZenecaAZN | 163.83 | -2.70% | $254.08B | 24.53 | 1.93% | +12.1% | D 36 |
Reference only, not investment advice. A screen is a starting point, not a buy list. Quant Rating method: Data & Methodology.